8-K: Evolent Health Announces Q4 and Full Year 2024 Results: Revenue Up, Focus on Profitability

Evolent Health reports revenue growth of 16.3% for Q4 2024 and 30.1% for the full year, alongside strategic contract amendments aimed at boosting future profitability.

Summary

• Evolent Health announced its financial results for the three months and full year ended December 31, 2024.
• Revenue for Q4 2024 reached $646.5 million, a 16.3% increase compared to the same period in 2023.
• Full-year 2024 revenue totaled $2,554.7 million, representing a 30.1% growth over 2023.
• The company reported a net loss attributable to common shareholders of $30.6 million for Q4 2024 and $93.5 million for the full year.
• Adjusted EBITDA for Q4 2024 was $22.6 million, with a margin of 3.5%.
• Full-year 2024 Adjusted EBITDA reached $160.5 million, resulting in a 6.3% margin.
• Evolent signed contract amendments expected to yield $115 million in annual improvement for 2025 in both net income and Adjusted EBITDA, exceeding the initial target of $100 million.
• The company achieved a 100% partner contract retention rate across its top customers, representing over 90% of 2024 revenue.
• Two new revenue agreements were signed during the quarter.
• For Q1 2025, revenue is expected to be in the range of $440 million to $470 million, and Adjusted EBITDA is expected to be between $31 million and $37 million.
• Full-year 2025 revenue is projected to be approximately $2.06 billion to $2.11 billion, representing 15%-18% annual growth after adjusting for one-time contract changes.
• Adjusted EBITDA for the full year 2025 is expected to be in the range of $135 million to $165 million.
• The company anticipates deploying approximately $35 million in cash for capitalized software development during 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company shows strong revenue growth and customer retention, the net losses and reliance on a few key partners temper the overall outlook. The improved contract terms and future guidance provide some optimism.

Positives

• Significant revenue growth was achieved in both Q4 and full-year 2024.
• High customer retention rate indicates strong customer satisfaction and value proposition.
• Strategic contract amendments are expected to drive substantial improvements in profitability.
• New revenue agreements signed during the quarter demonstrate continued market demand for Evolent's solutions.
• The company is expanding relationships with existing clients to include new health plans, geographies, and lines of business, including Medicare Advantage.

Negatives

• The company reported a net loss attributable to common shareholders for both Q4 and full-year 2024.
• Elevated oncology costs continued to impact results during the quarter.
• Adjusted EBITDA margin, while positive, could be higher.

Risks

• The company's reliance on a few large partners poses a risk if those relationships are terminated or renegotiated.
• Increasing risk-sharing arrangements with partners could expose Evolent to greater financial risk.
• The growth and success of partners are subject to factors outside of Evolent's control.
• Inaccurate or untimely information from customers could negatively impact performance.
• The company faces risks related to completed and future acquisitions, investments, alliances and joint ventures.
• The company's ability to achieve profitability in the future is not guaranteed.

Future Outlook

Evolent expects Q1 2025 revenue to be in the range of $440 million to $470 million and Adjusted EBITDA to be between $31 million and $37 million; full year 2025 revenue is projected to be approximately $2.06 billion to $2.11 billion and Adjusted EBITDA to be in the range of $135 million to $165 million.

Management Comments

• Evolent delivered fourth quarter and 2024 full-year results within the outlook range we provided in November, despite continued elevated oncology costs during the quarter.
• We also ended the year with 100% retention across our top customers which together represent over 90% of our 2024 revenue.
• Looking ahead, the recent changes we made in certain of our Performance Suite contracts as well as our assumptions for medical cost inflation make us feel confident in our financial outlook.
• Evolent remains an incredibly unique asset; We have a strong team, a product that our customers value and a clinical approach that both manages healthcare affordability while also enabling the kind of care we would want for our family members.

Industry Context

The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions, positioning the company to capitalize on industry trends focused on cost management and improved health outcomes.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific details of Evolent's contracts and service offerings.
• However, companies like Optum, Cognizant, and Accenture also operate in the healthcare technology and services space.
• Comparing Evolent's growth rate, EBITDA margins, and customer retention to these companies would provide a better understanding of its relative performance.
• For example, Optum, a subsidiary of UnitedHealth Group, is a major player in healthcare services and technology, and its financial performance is often used as a benchmark in the industry.
• Similarly, Cognizant and Accenture have significant healthcare consulting and technology practices, and their growth rates and profitability can be used to assess Evolent's performance.

Stakeholder Impact

• Shareholders may be concerned about the net losses, but encouraged by the revenue growth and improved contract terms.
• Customers benefit from Evolent's solutions aimed at improving health outcomes and managing costs.
• Employees are part of a company experiencing growth and strategic changes.
• Suppliers and creditors are impacted by Evolent's financial performance and growth trajectory.

Next Steps

• Evolent will hold a conference call on February 20, 2025, to discuss its financial performance and related matters.
• The company expects to deploy approximately $35 million in cash for capitalized software development during 2025.

Key Dates